APA (7th ed.) Citation

Schubert, M., Schmitt, A., Sellner, L., Neuber, B., Kunz, J., Wuchter, P., . . . Schmitt, M. (2019). Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: A unicentre phase I/II clinical trial protocol. BMJ open, 9(5), . https://doi.org/10.1136/bmjopen-2018-026644

Chicago Style (17th ed.) Citation

Schubert, Maria-Luisa, et al. "Treatment of Patients with Relapsed or Refractory CD19+ Lymphoid Disease with T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector: A Unicentre Phase I/II Clinical Trial Protocol." BMJ Open 9, no. 5 (2019). https://doi.org/10.1136/bmjopen-2018-026644.

MLA (9th ed.) Citation

Schubert, Maria-Luisa, et al. "Treatment of Patients with Relapsed or Refractory CD19+ Lymphoid Disease with T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector: A Unicentre Phase I/II Clinical Trial Protocol." BMJ Open, vol. 9, no. 5, 2019, https://doi.org/10.1136/bmjopen-2018-026644.